Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jun 3;13(6):1-6.
doi: 10.1080/21645515.2017.1285477. Epub 2017 Mar 8.

Phase I clinical trial of idiotypic DNA vaccine administered as a complex with polyethylenimine to patients with B-cell lymphoma

A N Meleshko  1 , N A Petrovskaya  2 , N Savelyeva  3 , K P Vashkevich  1 , S N Doronina  1 , N V Sachivko  2
Affiliations

Phase I clinical trial of idiotypic DNA vaccine administered as a complex with polyethylenimine to patients with B-cell lymphoma

A N Meleshko et al. Hum Vaccin Immunother. .

Abstract

We report on the design of a phase I, non-randomized, open-label study of idiotypic DNA vaccination in patients with B-cell non-Hodgkin's lymphoma (ISRCTN31090206). The study uses DNA fusion gene vaccination encoding patient-specific single chain variable fragment, or idiotype, linked to an immunostimulatory sequence. Two types of immunostimulatory sequence are being explored: potato virus X coat protein and human chemokine MIP3α. Linear polyethylenimine with low molecular weight (8 kDa) is used as a synthetic vehicle for vaccine delivery. Humoral and T-cellular immune responses to vaccination will be measured by ELISA and ELISPOT, respectively. The primary study endpoints are safety, tolerability and immunogenicity of DNA-PEI vaccination.

Keywords: DNA vaccine; cancer vaccine; idiotype; lymphoma; polyethylenimine.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Constructions of DNA-vaccines. HL2 – helical linker 2: AEAAAKEAAAKEAAAK, LP – leader peptide, ATG и TAA – start- and stop-codons for protein translation, Restriction sites: Rs1 – BamHI or KpnI, Rs2 – SalI or HindIII, Rs3 – NotI, Rs4 – NdeI.
Figure 2.
Figure 2.
Overall treatment plan.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Okeanov AE, Moiseyev PI, Levin LF, et al.. Статистика онкологических заболеваний в Республике Беларусь (2005–2014) [Statistics of oncological diseases in the Republic of Belarus (2005–2014)]. Minsk, Belarus: N.N. Alexandrov National Cancer Centre of Belarus; 2015. Russian.
    1. Armitage JO. Non-Hodgkin lymphomas (2nd ed). Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2010.
    1. Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med. 1992;327(17):1209-1215; PMID: 1406793; https://doi.org/ 10.1056/NEJM199210223271705 - DOI - PubMed
    1. Bendandi M, Gocke CD, Kobrin CB, Benko FA, Sternas LA, Pennington R, Watson TM, Reynolds CW, Gause BL, Duffey PL, et al.. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med. 1999;5(10):1171-1177; PMID: 10502821; https://doi.org/ 10.1038/13928 - DOI - PubMed
    1. Timmerman JM, Vose JM, Czerwinski DK, Weng WK, Ingolia D, Mayo M, Denney DW, Levy R. Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma. Leuk Lymphoma. 2009;50(1):37-46; PMID: 19125383; https://doi.org/ 10.1080/10428190802563355 - DOI - PMC - PubMed

Publication types

MeSH terms

Associated data

LinkOut - more resources